Perforomist
Perforomist is a long-acting beta2-adrenergic agonist (LABA). It works by relaxing the smooth muscles of the airways in the lungs, helping to keep them open and making it easier to breathe. It is administered using a standard jet nebulizer connected to an air compressor.
Dosage by Body Weight
The standard dose for adults with COPD is one 20 mcg/2 mL unit-dose vial inhaled twice daily (once in the morning and once in the evening) using a nebulizer. Do not exceed 2 vials (40 mcg) in a 24-hour period. Perforomist is not intended for acute bronchospasm rescue therapy.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness of Perforomist in pediatric patients have not been established. It is not indicated for children. |
Formulation
Purpose
Long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Generic Name
Formoterol fumarateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.